Now in @natchem.nature.com: Antibodies dominate drug development—but they’re big, costly, and can trigger immune reactions. #McGill professors Hanadi Sleiman & Maureen McKeague introduce Alenomers: barcoded aptamers with antibody‑level chemical diversity, screenable at massive scale buff.ly/BKKN4zS
